FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their ...
FDA Approves First Medication for Obstructive Sleep Apnea - U.S.
Today, the FDA approved the first medication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity, to be used in combination with a reduced-calorie diet and...
News Release - Eli Lilly and Company
Apr 17, 2024 · Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea ...
Dec 20, 2024 · The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity -- the first medication approved for the condition.
Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep …
Dec 23, 2024 · Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a...
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea ...
Dec 20, 2024 · The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted...
GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea - U.S. News …
Dec 23, 2024 · Zepbound, which was first approved for weight management in November 2023, now offers new hope for those with obesity and obstructive sleep apnea, Eli Lilly reported.
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Jan 10, 2025 · Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly…
Dec 23, 2024 · Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Eli Lilly expects FDA call on Zepbound for sleep apnea in near term - CNBC
Jun 21, 2024 · Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as...